logo
logo

Itabmed Completes Series A-Round Financing After Spin-Off

Dec 01, 2021•almost 4 years ago

Round Type

series a

Shanghai

Description

ITabMed today announced it has completed the spin-off iTAbTM (immunotherapy antibody) platform and closed $20M Series A-round financing. Earlier in this year, Evive Biotech (formerly Generon BioMed Ltd) and Dr. Xiaoqiang Yan formed a joint venture and established ITabMed Ltd. with the full support from Evive and its shareholders

Company Information

Company

I Tab Med

Location

Shanghai, Shanghai, China

About

ITabMed is a clinical-stage biotech company located in Shanghai, China. The company was founded in 2020 and is registered in Lin Gang Sci-Tech City, Shanghai. It was a spin-off entity from the former “Generon BioMed Ltd.”. The company is focused on immunotherapy drug research and development to treat cancer. (www.itabmed.com)